Antiviral protection following immunization correlates with humoral but not cell-mediated immunity

Immunology and Cell Biology

Volumn 88, Issue 4, 2010, Pages 461-467

  Panchanathan, Vijay ^a   Chaudhri, Geeta ^a   Karupiah, Gunasegaran ^a  

^a Biology and Environment   (Australia)

Author keywords

Antibody; Cytotoxic T lympohocyte; Memory; Poxvirus infection protective immunity; Vaccination

Indexed keywords

VIRUS VACCINE;

ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; ECTROMELIA VIRUS; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; MOUSE; MOUSEPOX; NONHUMAN; POXVIRUS INFECTION; SECONDARY INFECTION;

ANIMALS; ANTIBODY FORMATION; ANTIVIRAL AGENTS; ECTROMELIA VIRUS; FEMALE; FLOW CYTOMETRY; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNIZATION; IMMUNOLOGIC MEMORY; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES, CYTOTOXIC;

ANIMALIA; ECTROMELIA VIRUS; MUS; POXVIRIDAE; VARIOLA VIRUS;

EID: 77952242736     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2009.110     Document Type: Article

References (43)

1. Fenner F, Henderson DA, Arita I, Jezek A, Ladnyi ID. Smallpox and Its Eradication. World Health Organization: Geneva, 1988.
2. Fulginiti VA, Papier A, Lane JM, Neff JM, Henderson DA. Smallpox vaccination: a review, part II. Adverse events. Clin Infect Dis 2003; 37: 251-271.
3. Chaudhri G, Panchanathan V, Bluethmann H, Karupiah G. Obligatory requirement for antibody in recovery from a primary poxvirus infection. J Virol 2006; 80: 6339-6344.
4. Chaudhri G, Panchanathan V, Buller RM, van den Eertwegh AJ, Claassen E, Zhou J et al. Polarized type 1 cytokine response and cell-mediated immunity determine genetic resistance to mousepox. Proc Natl Acad Sci USA 2004; 101: 9057-9062.
5. Karupiah G. Type 1 and type 2 cytokines in antiviral defense. Vet Immunol Immunopathol 1998; 63: 105-109.
6. Karupiah G, Buller RM, Van Rooijen N, Duarte CJ, Chen J. Different roles for CD4+ and CD8+ T lymphocytes and macrophage subsets in the control of a generalized virus infection. J Virol 1996; 70: 8301-8309.
7. Karupiah G, Chen JH, Nathan CF, Mahalingam S, MacMicking JD. Identification of nitric oxide synthase 2 as an innate resistance locus against ectromelia virus infection. J Virol 1998; 72: 7703-7706.
8. Karupiah G, Fredrickson TN, Holmes KL, Khairallah LH, Buller RM. Importance of interferons in recovery from mousepox. J Virol 1993; 67: 4214-4226.
9. Fang M, Sigal LJ. Antibodies and CD8+ T cells are complementary and essential for natural resistance to a highly lethal cytopathic virus. J Immunol 2005; 175: 6829-6836.
10. Panchanathan V, Chaudhri G, Karupiah G. Interferon function is not required for recovery from a secondary poxvirus infection. Proc Natl Acad Sci USA 2005; 102: 12921-12926.
11. Panchanathan V, Chaudhri G, Karupiah G. Protective immunity against secondary poxvirus infection is dependent on antibody but not on CD4 or CD8 T-cell function. J Virol 2006; 80: 6333-6338.
12. Fang M, Cheng H, Dai Z, Bu Z, Sigal LJ. Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host. Virology 2006; 345: 231-243.
13. Xu RH, Fang M, Klein-Szanto A, Sigal LJ. Memory CD8+ T cells are gatekeepers of the lymph node draining the site of viral infection. Proc Natl Acad Sci USA 2007; 104: 10992-10997.
14. Ahmed R, Gray D. Immunological memory and protective immunity: understanding their relation. Science 1996; 272: 54-60.
15. Tscharke DC, Karupiah G, Zhou J, Palmore T, Irvine KR, Haeryfar SM et al. Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines. J Exp Med 2005; 201: 95-104.
16. Esteban DJ, Buller RM. Ectromelia virus: the causative agent of mousepox. J Gen Virol 2005; 86: 2645-2659.
17. Fenner F. Mouse-pox; infectious ectromelia of mice; a review. J Immunol 1949; 63: 341-373.
18. Roberts JA. Growth of ectromelia virus in the liver parenchymal cells of different strains of mouse. Nature 1964; 202: 1140-1141.
19. Gray D, Dullforce P, Jainandunsing S. Memory B cell development but not germinal center formation is impaired by in vivo blockade of CD40-CD40 ligand interaction. J Exp Med 1994; 180: 141-155.
20. Han S, Zheng B, Takahashi Y, Kelsoe G. Distinctive characteristics of germinal center B cells. Semin Immunol 1997; 9: 255-260.
21. Alexander-Miller MA, Leggatt GR, Berzofsky JA. Selective expansion of high- or lowavidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci USA 1996; 93: 4102-4107.
22. Hofmann M, Radsak M, Rechtsteiner G, Wiemann K, Günder M, Bien-Gräter U et al. Tcell avidity determines the level of CTL activation. Eur J Immunol 2004; 34: 1798-1806.
23. Derby M, Alexander-Miller M, Tse R, Berzofsky J. High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL. J Immunol 2001; 166: 1690-1697.
24. Chaudhri G, Quah BJ, Wang Y, Tan AH, Zhou J, Karupiah G et al. T cell receptor sharing by cytotoxic T lymphocytes facilitates efficient virus control. Proc Natl Acad Sci USA 2009; 106: 14984-14989.
25. Ramshaw IA, Ramsay AJ, Karupiah G, Rolph MS, Mahalingam S, Ruby JC. Cytokines and immunity to viral infections. Immunol Rev 1997; 159: 119-135.
26. Belz GT, Xie W, Doherty PC. Diversity of epitope and cytokine profiles for primary and secondary influenza a virus-specific CD8+ T cell responses. J Immunol 2001; 166: 4627-4633.
27. Cho BK, Wang C, Sugawa S, Eisen HN, Chen J. Functional differences between memory and naive CD8T cells. Proc Natl Acad Sci USA 1999; 96: 2976-2981.
28. Slifka MK, Whitton JL. Activated and memory CD8+ T cells can be distinguished by their cytokine profiles and phenotypic markers. J Immunol 2000; 164: 208-216.
29. Veiga-Fernandes H, Walter U, Bourgeois C, McLean A, Rocha B. Response of naive and memory CD8+ T cells to antigen stimulation in vivo. Nat Immunol 2000; 1: 47-53.
30. Lustig S, Maik-Rachline G, Paran N, Melamed S, Israely T, Erez N et al. Effective postexposure protection against lethal orthopoxviruses infection by vaccinia immune globulin involves induction of adaptive immune response. Vaccine 2009; 27: 1691-1699.
31. Wyatt LS, Earl PL, Eller LA, Moss B. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Natl Acad Sci USA 2004; 101: 4590-4595.
32. Belyakov IM, Earl P, Dzutsev A, Kuznetsov VA, Lemon M, Wyatt LS et al. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci USA 2003; 100: 9458-9463.
33. Earl PL, Americo JL, Wyatt LS, Eller LA, Whitbeck JC, Cohen GH et al. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 2004; 428: 182-185.
34. Stittelaar KJ, van Amerongen G, Kondova I, Kuiken T, van Lavieren RF, Pistoor FH et al. Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. J Virol 2005; 79: 7845-7851.
35. Edghill-Smith Y, Golding H, Manischewitz J, King LR, Scott D, Bray M et al. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med 2005; 11: 740-747.
36. Meseda CA, Garcia AD, Kumar A, Mayer AE, Manischewitz J, King LR et al. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model. Virology 2005; 339: 164-175.
37. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007; 357: 1903-1915.
38. Dorner T, Radbruch A. Antibodies and B cell memory in viral immunity. Immunity 2007; 27: 384-392.
39. Hammarlund E, Lewis MW, Hansen SG, Strelow LI, Nelson JA, Sexton GJ et al. Duration of antiviral immunity after smallpox vaccination. Nat Med 2003; 9: 1131-1137.
40. Jackson RJ, Maguire DJ, Hinds LA, Ramshaw IA. Infertility in mice induced by a recombinant ectromelia virus expressing mouse zona pellucida glycoprotein 3. Biol Reprod 1998; 58: 152-159.
41. Scalzo AA, Farrell HE, Karupiah G. Techniques for studying murine natural killer cells in defense against viral infection. Methods Mol Biol 2000; 121: 163-177.
42. Coulibaly S, Bruhl P, Mayrhofer J, Schmid K, Gerencer M, Falkner FG. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection. Virology 2005; 341: 91-101.
43. Ferrier-Rembert A, Drillien R, Tournier JN, Garin D, Crance JM. Short- and long-term immunogenicity and protection induced by non-replicating smallpox vaccine candidates in mice and comparison with the traditional 1st generation vaccine. Vaccine 2008; 26: 1794-1804.